Throughout induced hypoglycemia, semaglutide didn't change the counter regulatory responses of greater glucagon compared to placebo and didn't impair the lower of C-peptide in clients with type 2 diabetes. para reducir el riesgo de eventos cardiovasculares serios tales como ataque card&ia